Search company, investor...
Real Time Genomics company logo

Real Time Genomics


Series B | Alive

Total Raised


Last Raised

$5M | 10 yrs ago

About Real Time Genomics

Real Time Genomics offers software tools and applications for the extraction of value from genomic data. Its competency lies in applying the combination of its patented core technology and computational expertise in algorithms to solve problems in genomic analysis.

Headquarters Location

Level 1, South Bloc 19 Knox St

Hamilton, 3204,

New Zealand

+64 7859 1007

Missing: Real Time Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Real Time Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Real Time Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Real Time Genomics is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Real Time Genomics Patents

Real Time Genomics has filed 1 patent.

The 3 most popular patent topics include:

  • Bioinformatics
  • Biotechnology
  • Computational phylogenetics
patents chart

Application Date

Grant Date


Related Topics




Bioinformatics, Computational phylogenetics, Molecular biology, Genetics, Biological databases


Application Date


Grant Date



Related Topics

Bioinformatics, Computational phylogenetics, Molecular biology, Genetics, Biological databases



Latest Real Time Genomics News

TOMA Biosciences Partners with Real Time Genomics to Develop Clinical Analysis Tools for Molecular Cancer Tumor Profiling

Jul 12, 2016

SeraCare Life Sciences and TOMA Biosciences Enter Into Co-development Partnership TOMA Biosciences and Real Time Genomics announce a partnership to develop novel analysis tools to process next-generation sequencing data from clinical tumor samples. Their goal is to improve somatic mutation identification to meet clinical regulatory requirements, so these tools can become an integral part of clinical testing. Tumor profiling, using targeted next-generation sequencing of actionable cancer genes, is becoming the standard approach for selecting targeted therapies for refractory cancer patients. However, the software used by most laboratories to profile tumors originated in academic research projects, such as The Cancer Genome Atlas and the International Cancer Genome Consortium. These academic tools were designed for research protocols in which a sample of normal tissue is obtained and sequenced in parallel to the tumor sample, in order to help distinguish cancer somatic mutations from germline variants. This presents a major challenge for the clinic, where a normal sample is rarely collected from a patient during a tumor tissue biopsy or in plasma cell-free tumor DNA profiling. In addition, large-scale biobanks of archived tumor samples, which are being used for retrospective analysis of patient outcomes, largely lack matched normal tissue samples. “Most clinical pathology laboratories only have access to tumor tissue,” said Francisco M. De La Vega, Vice President of Bioinformatics and Distinguished Scientific Fellow at TOMA Biosciences. “We’ve worked with Real Time Genomics to develop a ‘tumor-only’ somatic mutation caller that is tuned to the TOMA OS-Seq™ tumor profiling technology. Our statistically rigorous approach allows us to accurately identify somatic mutations and segregate them from the germline variants using NGS data from tumor samples. We’ve validated this new analysis tool with simulated data and reference samples, and it significantly outperforms the publicly available academic tools and filtering schemes used by most labs. Critically, this software has been developed using a controlled development process, which is important to meet regulatory concerns.” The new algorithms developed for this software and the benchmarking results were presented by Dr. De La Vega on July 9 at the High-Throughput Sequencing Algorithms and Applications meeting, as part of the International Society for Computational Biology annual conference held in Orlando, Florida. TOMA Biosciences is partnering with Real Time Genomics, a premier developer of commercial software for the analysis of next-generation sequencing data that is based in Hamilton, New Zealand. “We’ve already developed an extensive portfolio of genomic analysis tools and intellectual property for a wide range of applications,” said Graham Gaylard, Founder and CEO of Real Time Genomics. “We are now happy to leverage our portfolio to help TOMA develop new clinical grade analysis software to more accurately profile cancer tumor samples. As true partners, we’re discovering new ways to look at the data and new ways to more accurately analyze it, with the aim of eliminating the inconsistent results that currently plague the field.” For more information, please contact: Victoria Lavi TOMA Director of Marketing Operations Email: victoria.lavi(at)tomabio(dot)com

Real Time Genomics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Real Time Genomics Rank

Real Time Genomics Frequently Asked Questions (FAQ)

  • Where is Real Time Genomics's headquarters?

    Real Time Genomics's headquarters is located at Level 1, South Bloc, Hamilton.

  • What is Real Time Genomics's latest funding round?

    Real Time Genomics's latest funding round is Series B.

  • How much did Real Time Genomics raise?

    Real Time Genomics raised a total of $8M.

  • Who are the investors of Real Time Genomics?

    Investors of Real Time Genomics include Catamount Ventures and Lightspeed Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.